A real-life study of the efficacy and safety of post-HSCT treatment with Ponatinib in patients with High-Risk Philadelphia Chromosome Positive Leukemia
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology